Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of food microbiology

• Publication date

  2012-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ijfoodmicro.2012.04.012PMID 22609000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits.

  2011cited by this paper
• Candida albicans interactions with epithelial cells and mucosal immunity.

  2011cited by this paper
• Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes

  2010cited by this paper
• Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells

  2010cited by this paper
• Bloodstream yeast infections: a 15-month survey

  2009cited by this paper
• Epithelial GM-CSF Induction by Candida glabrata

  2009cited by this paper
• In Vivo and In Vitro Studies on Virulence and Host Responses to Saccharomyces cerevisiae Clinical and Non-Clinical Isolates

  2009cited by this paper
• Intestinal barrier function: molecular regulation and disease pathogenesis.

  2009cited by this paper
• Comparison of Saccharomyces cerevisiae strains of clinical and nonclinical origin by molecular typing and determination of putative virulence traits

  2008cited by this paper
• [Saccharomyces cerevisiae fungemia associated with multifocal pneumonia in a patient with alcohol-related hepatic cirrhosis].

  2008cited by this paper
• Safety assessment of dairy microorganisms: the hemiascomycetous yeasts.

  2008cited by this paper
• Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin

  2008cited by this paper
• Cytotoxic and cytokine-inducing properties of Candida glabrata in single and mixed oral infection models.

  2007cited by this paper
• Candida glabrata: an emerging oral opportunistic pathogen.

  2007cited by this paper
• Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia

  2007cited by this paper
• AAV transcytosis through barrier epithelia and endothelium.

  2006cited by this paper
• A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors

  2006cited by this paper
• Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration.

  2005cited by this paper
• Invasive Saccharomyces infection: a comprehensive review.

  2005cited by this paper
• Saccharomyces cerevisiae fungemia: an emerging infectious disease.

  2005cited by this paper
• Molecular characterization of clinical Saccharomyces cerevisiae isolates and their association with non-clinical strains.

  2004cited by this paper
• Yeasts in Food

  2003cited by this paper
• Spoilage yeasts in the wine industry.

  2003cited by this paper
• 8 – Yeasts in dairy products

  2003cited by this paper
• Fatal Saccharomyces cerevisiae Aortic Graft Infection

  2002cited by this paper
• Seven cases of fungemia with Saccharomyces boulardii in critically ill patients

  2002cited by this paper
• Emerging pathogens.

  2000cited by this paper
• Production of IFN-gamma is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission.

  2000cited by this paper
• Emergence of Saccharomyces cerevisiae as a human pathogen: Implications for biotechnology

  1999cited by this paper
• The prevalence and control of spoilage yeasts in foods and beverages

  1999cited by this paper
• Species Identification and Virulence Attributes ofSaccharomyces boulardii (nom. inval.)

  1998cited by this paper
• Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice

  1995cited by this paper
• New and emerging yeast pathogens

  1995cited by this paper
• Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae.

  1994cited by this paper
• Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae

  1994cited by this paper
• Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy.

  1993cited by this paper
• Yeasts in dairy products.

  1990cited by this paper
• Fever of unknown origin secondary to brewer's yeast ingestion.

  1976cited by this paper

• The Biotherapeutic Potential of a Novel Probiotic Kluyveromyces marxianus Isolated from a Sourdough Starter Against Vaginal Candida albicans Strains

  2025cites this paper
• Comparative genomics of infective Saccharomyces cerevisiae strains reveals their food origin

  2023cites this paper
• Characterization of kefir yeasts with antifungal capacity against Aspergillus species

  2022cites this paper
• Epidemiological Characterization of Clinical Fungal Isolates from Pauls Stradinš Clinical University Hospital, Latvia: A 4-Year Surveillance Report

  2021cites this paper
• Virulence Factors and in-Host Selection on Phenotypes in Infectious Probiotic Yeast Isolates (Saccharomyces ‘boulardii’)

  2021cites this paper
• Virulence related traits in yeast species associated with food; Debaryomyces hansenii, Kluyveromyces marxianus, and Wickerhamomyces anomalus

  2021cites this paper
• Antiproliferative activity of green, black tea and olive leaves polyphenols subjected to biosorption and in vitro gastrointestinal digestion in Caco-2 cells.

  2020cites this paper
• Baker's Yeast Clinical Isolates Provide a Model for How Pathogenic Yeasts Adapt to Stress.

  2019cites this paper
• NOTE show low levels of traversal across Saccharomyces cerevisiae the human blood brain barrier in vitro

  2019cites this paper
• Characterization of the nuclear RNase P of Candida glabrata and improvement of genome editing tools

  2018cites this paper
• Assessment of the application for renewal of authorisation of Actisaf® Sc47 (Saccharomyces cerevisiae CNCM I‐4407) for lambs for fattening, minor dairy ruminants, horses and pigs for fattening

  2018cites this paper
• Saccharomyces cerevisiae show low levels of traversal across human endothelial barrier in vitro

  2017cites this paper
• NOTE show low levels of traversal across Saccharomyces cerevisiae the human blood brain barrier in vitro

  2017cites this paper
• Whole Genome Analysis of 132 Clinical Saccharomyces cerevisiae Strains Reveals Extensive Ploidy Variation

  2016cites this paper
• Opportunistic Strains of Saccharomyces cerevisiae: A Potential Risk Sold in Food Products

  2016cites this paper
• Tipping the balance both ways: drug resistance and virulence in Candida glabrata.

  2015cites this paper
• Invasive Saccharomyces cerevisiae in a liver transplant patient: case report and review of infection in transplant recipients

  2015cites this paper
• Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans.

  2015cites this paper
• Immunoproteomic profiling of Saccharomyces cerevisiae systemic infection in a murine model.

  2015cites this paper
• Pathogenic Potential of Saccharomyces Strains Isolated from Dietary Supplements

  2014cites this paper
• Saccharomyces unisporus: Biotechnological Potential and Present Status.

  2013cites this paper
• Investigating the role of intestinal microflora in the aetiology, symptom scores and life quality of people with coeliac disease

  2013cites this paper